Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 3/2006

01-12-2006

Left main coronary thrombosis with essential thrombocythemia

Authors: Zekeriya Nurkalem, Nevzat Uslu, Sevket Gorgulu, Mehmet Eren

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2006

Login to get access

Abstract

Essential thrombocythemia is a disorder that causes persistent increase in the platelet count. The disease is associated with an elevated risk of thrombosis. A 71-year-old woman was diagnosed with left main coronary thrombosis after an angiogram due to stable angina. One week before the angiogram was taken the patient had also been diagnosed with essential thrombocythemia. After appropriate medical treatment for 5 days the patient underwent an excimer laser treatment, which failed in dissolving the thrombus. Before the patient underwent coronary surgery, thrombopheresis was performed in order to reduce the platelet count. After a successful coronary operation the patient improved completely.
Literature
1.
go back to reference Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755–761CrossRefPubMed Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755–761CrossRefPubMed
2.
go back to reference Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556–562PubMed Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556–562PubMed
3.
go back to reference Harrison CN, Gale RE, Machin SJ, Linch DC (1999) A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 93:417–424PubMed Harrison CN, Gale RE, Machin SJ, Linch DC (1999) A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 93:417–424PubMed
4.
go back to reference van Genderen PJ, Lucas IS, van Strik R, Vuzevski VD, Prins FJ, van Vliet HH, et al (1996) Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost 76:333–338PubMed van Genderen PJ, Lucas IS, van Strik R, Vuzevski VD, Prins FJ, van Vliet HH, et al (1996) Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost 76:333–338PubMed
5.
go back to reference Michaels AD, Whisenant B, MacGregor JS (1998) Multivessel coronary thrombosis treated with abciximab (ReoPro) in a patient with essential thrombocythemia. Clin Cardiol 21:134–138PubMedCrossRef Michaels AD, Whisenant B, MacGregor JS (1998) Multivessel coronary thrombosis treated with abciximab (ReoPro) in a patient with essential thrombocythemia. Clin Cardiol 21:134–138PubMedCrossRef
6.
go back to reference Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C, et al (1995) Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 74:1225–1230PubMed Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C, et al (1995) Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 74:1225–1230PubMed
7.
go back to reference Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ (2002) Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost 87:802–807PubMed Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ (2002) Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost 87:802–807PubMed
8.
go back to reference Daya SK, Gowda RM, Landis WA, Khan IA (2004) Essential thrombocythemia-related acute ST-segment elevation myocardial infarction. A case report and literature review. Angiology 55:319–323CrossRefPubMed Daya SK, Gowda RM, Landis WA, Khan IA (2004) Essential thrombocythemia-related acute ST-segment elevation myocardial infarction. A case report and literature review. Angiology 55:319–323CrossRefPubMed
9.
go back to reference Topaz O, Ebersole D, Das T, Alderman EL, Madyoon H, Vora K, et al (2004) (the CARMEL multicenter trial). Excimer laser angioplasty in acute myocardial infarction. Am J Cardiol 93:694–701CrossRefPubMed Topaz O, Ebersole D, Das T, Alderman EL, Madyoon H, Vora K, et al (2004) (the CARMEL multicenter trial). Excimer laser angioplasty in acute myocardial infarction. Am J Cardiol 93:694–701CrossRefPubMed
Metadata
Title
Left main coronary thrombosis with essential thrombocythemia
Authors
Zekeriya Nurkalem
Nevzat Uslu
Sevket Gorgulu
Mehmet Eren
Publication date
01-12-2006
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2006
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-006-9016-5

Other articles of this Issue 3/2006

Journal of Thrombosis and Thrombolysis 3/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.